Orphan Drugs Market By Type (Biological, Non Biological), By Therapeutic (Oncology, Hematology, Neurology) , Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: Jun 20, 2016

Key Findings


The global orphan drugs market is expected to grow at the CAGR of 12.6 % during 2016-2022 and is expected to reach $205700 million till 2022.An orphan drug is a pharmaceutical agent that has being developed specifically to treat a rare disease. There are many factors that drive’s the global orphan drugs market.The major driving factor that drives this market is increase in investment from pharmaceutical companies which are facing loses from other conventional products. Due to favorable government policies, the companies that are in the development of orphan drugs have monopolized the market. Government policies such as providing reimbursement for orphan drug discovery and development is driving the growth of orphan drug market. Rising incidence of orphan disease is also a factor to boost the global orphan drug market. There are around 7000 rare types of rare diseases and disorders, these numbers are increasing day by day. 80% of rare diseases are genetically originated and rest are result of infections, environmental causes and allergies. Around 50% of genetic diseases are in children. 30 % of children with rare diseases cannot live for more than 5 years.High healthcare expenditure and awareness towards orphan diseases is also a factor that builds the global orphan drugs market.

The Orphan drugs is made up with technologically advanced machineries, diverse R&D approaches and skilled professionals. This all adds up the cost of orphan drugs, orphan drugs is not in the reach of common people due to its cost. This acts as a barrier in the growth of the global orphan drugs market.
The high initial investment,clinical studies and regulatory obstacles and hurdles is one of the major constraining factors in the growth of orphan drugs market. Thestandards and regulatory framework vary from country to country making it difficult for companies to operate on the global level. It requires a high initial investment in manufacturing orphan drug, hence only the companies with high capital and able to invest in this type of big projects is consideredto enter in this business segment.


Market Segment Insight


The global orphan drugs market is majorly segmented intotype, therapeutic, type, and regional outlook.In type market is divided into biological and non-biological. The biological product segment is the fastest growing product segment supporting their greater efficiency over non biologics. Around 80% of orphan diseases is genetic in nature, biological orphans are best suited for targeted therapies.In therapeutic segment market is divided into oncology, hematology, neurology, and others. Oncology segment generates the largest amount of revenue. In regional outlook the market is divided into North America, Europe, Asia pacific and rest of the world. North America is the fastest growing orphan drug market. The major reason for the growth of North America is incentives offered by US food and drug administrations, like extended market exclusivity for orphan drugs and drugs development. Europe is also one of the growing country. Established regulatory and reimbursement framework is the key reason for the growth of European region. Prevalence of genetic diseases in highly populated countries such as India, China and Africa etc. is attracting orphan drugs manufacturers to invest in this market. Asia Pacific region is expected to grow in near future.


Regional Insight


Globally the global orphan drugs market is divided into North America, Europe, Asia Pacific and Rest of the World.North America is the fastest growing orphan drug market. The major reason for the growth of North America is incentives offered by US food and drug administrations, like extended market exclusivity for orphan drugs and drugs development, high prevalence rate of orphan diseases in North America is also a major reason in fueling up the global market.Europe is also one of the growing country. Established regulatory and reimbursement framework is the key reason for the growth of European region, growth of population is also a major reason for the growth of global orphan drugs in this market.Asia Pacific region is expected to grow in near future. Rest of the world is also expecting the growth in near future. Prevalence of genetic diseases in highly populated countries such as India, China and Africa etc. is attracting orphan drugs manufacturers to invest in this market. Rising rare diseases in this region, growth of population are the key factors.


Competitive Insights


Some of the keymarket players are Bayer Healthcare Pharmaceuticals, Baxter International, Amgen, Alexion Pharmaceutical, Actelion Pharmaceutical, Bristol-Mayers Squibb, BoehringerInglheim GmbH, Biomarin Pharmaceutical Inc., Johnson& Johnson, F. Hoffmann-La Roche AG, Cangene Corp., etc. Acquisitions, new product development, collaborations, joint ventures, mergers and expansions are the key strategies adopted by the market players to sustain in the market. in June 2016 Johnson & Johnson acquired Vogue International.

CHAP 1. METHODOLOGY & SCOPE 12
1.1. RESEARCH METHODOLOGY 12
1.2. RESEARCH SCOPE & ASSUMPTIONS 12
1.3. LIST OF DATA SOURCES 12


CHAP 2. EXECUTIVE SUMMARY 13
2.1. GLOBAL ORPHAN DRUGS MARKET SUMMARY & KEY BUYING CRITERIA 13
2.2. GLOBAL ORPHAN DRUGS MARKET OUTLOOK 13
2.3. MARKET SEGMENTATION ANALYSIS 13
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 13
2.5. GLOBAL ORPHAN DRUGS MARKET VALUE CHAIN ANALYSIS 13
2.6. VENDOR LANDSCAPE 13


CHAP 3. GLOBAL ORPHAN DRUGS MARKET 14
3.1. MARKET DRIVER ANALYSIS 14
3.1.1. RISE IN INCIDENCE OF RARE FORMS OF CANCER 14
3.1.2. RISING HEALTHCARE EXPENDITURE 14
3.1.3. RISE IN AGEING POPULATION 14
3.1.4. INDUSTRY COLLABORATION 14
3.2. MARKET RESTRAINT ANALYSIS 14
3.2.1. HIGH INITIAL INVESTMENT 14
3.2.2. CLINICAL STUDY HURDLES 14
3.3. KEY OPPORTUNITIES 14
3.3.1. INCREASING PREVALENCE OF CHRONIC DISEASES 14
3.3.2. GOVERNMENT INITIATIVES TOWARDS RARE DISEASES 14
3.4. CHALLENGES 14
3.4.1. INCREASING COMPETITIONS FROM GENERICS INDUSTRY 14
3.4.2. HIGH COST OF ORPHAN DRUGS 14


CHAP 4. INDUSTRY ANALYSIS 15
4.1. GLOBAL ORPHAN DRUGS MARKET– PORTER’S FIVE FORCE MODEL 15
4.2. GLOBAL ORPHAN DRUGS MARKET– PESTEL ANALYSIS 15
4.3. GLOBAL ORPHAN DRUGS MARKET– GAP ANALYSIS 15


CHAP 5. GLOBAL ORPHAN DRUGS MARKET BY TYPE 2012-2022 ($ MILLION) 16
5.1. GLOBAL ORPHAN DRUGS MARKET BY BIOLOGICAL 2012-2022 ($ MILLION) 16
5.2. GLOBAL ORPHAN DRUGS MARKET BY NON BIOLOGICAL 2012-2022 ($ MILLION) 16


CHAP 6. GLOBAL ORPHAN DRUGS MARKET BY THERAPEUTIC 2012-2022 ($ MILLION) 17
6.1. GLOBAL ORPHAN DRUGS MARKET BY ONCOLOGY 2012-2022 ($ MILLION) 17
6.2. GLOBAL ORPHAN DRUGS MARKET BY HEMATOLOGY 2012-2022 ($ MILLION) 17
6.3. GLOBAL ORPHAN DRUGS MARKET BY NEUROLOGY 2012-2022 ($ MILLION) 17
6.4. GLOBAL ORPHAN DRUGS MARKET BY OTHERS 2012-2022 ($ MILLION) 17


CHAP 7. GLOBAL ORPHAN DRUGS MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 18
7.1. GLOBAL ORPHAN DRUGS MARKET BY REGION 2012-2022 ($ MILLION) 18
7.2. NORTH AMERICA 18
7.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
7.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 18
7.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
7.2.3.1. U.S. 18
7.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
7.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
7.2.3.2. CANADA 18
7.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
7.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
7.2.3.3. MEXICO 18
7.2.3.3.1. MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 18
7.2.3.3.2. MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 18
7.3. EUROPE 19
7.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 19
7.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3.3.1. GERMANY 19
7.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3.3.2. UK 19
7.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3.3.3. FRANCE 19
7.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3.3.4. SPAIN 19
7.3.3.4.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 19
7.3.3.4.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 19
7.3.3.5. REST OF EUROPE 19
7.3.3.5.1. REST OF EUROPE MARKET ESTIMATES AND FORECAST2012-2022($MILLION) 20
7.3.3.5.2. REST OF EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($MILLION) 20
7.4. ASIA PACIFIC 20
7.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 20
7.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.4.3.1. CHINA 20
7.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.4.3.2. INDIA 20
7.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
7.4.3.3. JAPAN 20
7.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($MILLION) 20
7.4.3.4. SOUTH KOREA 20
7.4.3.4.1. SOUTH KOREA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
7.4.3.4.2. SOUTH KOREA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($MILLION) 20
7.4.3.5. REST OF APAC 21
7.4.3.5.1. REST OF APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
7.4.3.5.2. REST OF APAC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
7.5. REST OF THE WORLD 21
7.5.1. REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
7.5.2. REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 21
7.5.3. REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
7.5.3.1. LATIN AMERICA 21
7.5.3.1.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
7.5.3.1.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
7.5.3.2. MIDDLE EAST AND AFRICA 21
7.5.3.2.1. MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
7.5.3.2.2. MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21


CHAP 8. COMPETITIVE LANDSCAPE 22
8.1. ABBVIE 23
8.1.2. SCOT ANALYSIS 23
8.1.3. PRODUCT BENCHMARKING 23
8.1.4. STRATEGIC INITIATIVES 23
8.2. ACORDA THERAPEUTICS 23
8.2.2. SCOT ANALYSIS 23
8.2.3. PRODUCT BENCHMARKING 23
8.2.4. STRATEGIC INITIATIVES 23
8.3. ACTELION PHARMACEUTICALS LTD. 23
8.3.2. SCOT ANALYSIS 23
8.3.3. PRODUCT BENCHMARKING 23
8.3.4. STRATEGIC INITIATIVES 23
8.4. AEGERION PHARMACEUTICALS 23
8.4.2. PRODUCT BENCHMARKING 23
8.4.3. STRATEGIC INITIATIVES 23
8.5. ALEXION PHARMACEUTICALS 23
8.5.2. SCOT ANALYSIS 23
8.5.3. PRODUCT BENCHMARKING 23
8.5.4. STRATEGIC INITIATIVES 23
8.6. AMGEN 23
8.6.2. SCOT ANALYSIS 23
8.6.3. PRODUCT BENCHMARKING 24
8.6.4. STRATEGIC INITIATIVES 24
8.7. BAXTER INTERNATIONAL 24
8.7.2. SCOT ANALYSIS 24
8.7.3. PRODUCT BENCHMARKING 24
8.7.4. STRATEGIC INITIATIVES 24
8.8. BAYER HEALTHCARE PHARMACEUTICALS 24
8.8.2. SCOT ANALYSIS 24
8.8.3. PRODUCT BENCHMARKING 24
8.8.4. STRATEGIC INITIATIVES 24
8.9. BIOMARIN PHARMACEUTICAL INC. 24
8.9.2. SCOT ANALYSIS 24
8.9.3. PRODUCT BENCHMARKING 24
8.9.4. STRATEGIC INITIATIVES 24
8.10. BOEHRINGER INGELHEIM GMBH 24
8.10.2. SCOT ANALYSIS 24
8.10.3. PRODUCT BENCHMARKING 24
8.10.4. STRATEGIC INITIATIVES 24
8.11. BRISTOL-MYERS SQUIBB 24
8.11.2. SCOT ANALYSIS 24
8.11.3. PRODUCT BENCHMARKING 24
8.11.4. STRATEGIC INITIATIVES 24
8.12. CANGENE CORP. 25
8.12.2. SCOT ANALYSIS 25
8.12.3. PRODUCT BENCHMARKING 25
8.12.4. STRATEGIC INITIATIVES 25
8.13. F. HOFFMANN-LA ROCHE AG 25
8.13.2. SCOT ANALYSIS 25
8.13.3. PRODUCT BENCHMARKING 25
8.13.4. STRATEGIC INITIATIVES 25
8.14. JOHNSON & JOHNSON 25
8.14.2. SCOT ANALYSIS 25
8.14.3. PRODUCT BENCHMARKING 25
8.14.4. STRATEGIC INITIATIVES 25
8.15. MERCK & CO., INC. 25
8.15.2. SCOT ANALYSIS 25
8.15.3. PRODUCT BENCHMARKING 25
8.15.4. STRATEGIC INITIATIVES 25

TABLE 1 GLOBAL ORPHAN DRUGS MARKET BY TYPE 2012-2022 ($ MILLION) 25
TABLE 2 GLOBAL ORPHAN DRUGS MARKET BY BIOLOGICAL 2012-2022 ($ MILLION) 25
TABLE 3 GLOBAL ORPHAN DRUGS MARKET BY NON BIOLOGICAL 2012-2022 ($ MILLION) 25
TABLE 4 GLOBAL ORPHAN DRUGS MARKET BY THERAPEUTIC 2012-2022 ($ MILLION) 26
TABLE 5 GLOBAL ORPHAN DRUGS MARKET BY ONCOLOGY 2012-2022 ($ MILLION) 26
TABLE 6 GLOBAL ORPHAN DRUGS MARKET BY HEMATOLOGY 2012-2022 ($ MILLION) 26
TABLE 7 GLOBAL ORPHAN DRUGS MARKET BY NEUROLOGY 2012-2022 ($ MILLION) 26
TABLE 8 GLOBAL ORPHAN DRUGS MARKET BY OTHERS 2012-2022 ($ MILLION) 26
TABLE 9 GLOBAL ORPHAN DRUGS MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 26
TABLE 10 GLOBAL ORPHAN DRUGS MARKET BY REGION 2012-2022 ($ MILLION) 26
TABLE 11 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 12 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 26
TABLE 13 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 14 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 15 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 16 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 17 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 18 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 19 MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 26
TABLE 20 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 26
TABLE 21 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 27
TABLE 22 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 23 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 24 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 25 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 26 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 27 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 28 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 29 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 30 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 31 REST OF EUROPE MARKET ESTIMATES AND FORECAST2012-2022($MILLION) 27
TABLE 32 REST OF EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($MILLION) 27
TABLE 33 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 34 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 27
TABLE 35 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 36 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 27
TABLE 37 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 27
TABLE 38 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 39 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 40 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 41 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($MILLION) 28
TABLE 42 SOUTH KOREA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 43 SOUTH KOREA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($MILLION) 28
TABLE 44 REST OF APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 45 REST OF APAC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 46 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 47 REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 28
TABLE 48 REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 49 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 50 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 51 MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 52 MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28

FIGURE 1 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
FIGURE 2 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 4 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 5 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 6 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 7 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 8 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 9 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 10 REST OF EUROPE MARKET ESTIMATES AND FORECAST2012-2022($MILLION) 29
FIGURE 11 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 12 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 13 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 14 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 15 SOUTH KOREA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 16 REST OF APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 17 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
FIGURE 18 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
FIGURE 19 MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)